Unrelated or Partially Matched Allogeneic Donor Stem Cells for Lymphoma, Myeloma, and Chronic Lymphocytic Leukemia.
Phase of Trial: Phase II
Latest Information Update: 28 Feb 2017
At a glance
- Drugs Busulfan (Primary) ; Cyclophosphamide (Primary)
- Indications Chronic lymphocytic leukaemia; Graft-versus-host disease; Lymphoma; Multiple myeloma
- Focus Therapeutic Use
- 17 Feb 2017 Planned End Date changed from 1 Dec 2019 to 1 Dec 2020.
- 22 Jan 2016 Planned End Date changed from 1 Jan 2016 to 1 Dec 2019 as reported by ClinicalTrials.gov.
- 06 Feb 2013 Planned end date changed from 1 Jan 2014 to 1 Jan 2016 as reported by ClinicalTrials.gov.